Executive summary
The UK regulates peptides under the Human Medicines Regulations 2012 (SI 2012/1916) and the Medicines Act 1968. The MHRA is the standalone regulator post-Brexit. Peptide medicines require a UK Marketing Authorisation (UKMA). Compounding is governed by Section 10 of the Medicines Act 1968. The MHRA actively investigates unlicensed peptide clinics and online vendors.
Intended-use rule
Medicinal status is assessed from the product's presentation, claims, and surrounding evidence of intended use. A not-for-human-use or research-purpose disclaimer is not decisive when the wider evidence points to medicinal use.
Authorities and legal categories
MHRA: marketing authorisation, borderlines, enforcement, specials, import licensing, pharmacovigilance.
GPhC: regulates pharmacy professionals and premises in Great Britain.
CAP (Committee of Advertising Practice) / ASA: advertising standards for non-broadcast marketing.
Border Force: applies border controls to imported goods, alongside the medicine-licensing decisions described in MHRA import guidance.
Key instruments:
Human Medicines Regulations 2012 (SI 2012/1916).
Medicines Act 1968, Section 10 — pharmacy compounding exemption.
SI 2013/1855 — FMD initial transposition.
SI 2019/62 — FMD safety features (disapplied post-Brexit for GB and NI).
Medicines and Medical Devices Act 2021 — post-Brexit framework.
- MHRA: marketing authorisation, clinical-trial authorisation, specials, and unlicensed medicine enforcement.
- GPhC: pharmacy context.
- ASA and CAP: advertising.
- Border Force: import controls.
Approved medicines
Licensed peptide-class medicines in the UK include semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro), liraglutide (Victoza, Saxenda), insulin analogues, teriparatide (Forsteo), leuprorelin (Prostap), goserelin (Zoladex), octreotide (Sandostatin), desmopressin, salmon calcitonin, and nafarelin (Synarel). All are prescription-only medicines (POM).
Source: MHRA marketing authorisations, https://www.gov.uk/government/publications/marketing-authorisations-granted-in-2026
Investigational use
Clinical trials in the UK operate under a separate regime from the EU CT Regulation. The MHRA can authorise trials through the national procedure. ILAP (Innovative Licensing and Access Pathway) offers accelerated engagement for innovative peptide therapeutics.
Compounding/manufacturing
Section 10 of the Medicines Act 1968 exempts pharmacists from requiring a manufacturer's licence when:
Preparing or dispensing in a registered pharmacy pursuant to a prescription;
Under the supervision of a pharmacist;
For an identified patient.
The exemption does not permit stockpiling or wholesale-like supply.
Specials (Regulation 167 of HMR 2012, also IR 2012/1916): An unlicensed medicinal product can be supplied if all conditions are met:
Unsolicited order;
Manufactured to a prescriber's specification;
For a patient under that prescriber's direct responsibility;
No suitable licensed alternative;
Made or imported by a holder of a Manufacturer's "Specials" Licence (MSL).
| Status route | Authority | Permitted context described | What it does not establish |
|---|---|---|---|
| Marketing authorisation | MHRA | A licensed product and use recorded in current UK authorization data | It does not authorize a different product, use, or presentation |
| Clinical-trial authorisation | MHRA | A national clinical-trial procedure for an A clinical-stage candidate with scientific or public relevance. Investigation is not approval, and a studied exposure is not a recommendation. परिभाषा का स्रोत: Scope and selection methodology · शब्दावली product | It is not marketing authorization |
| Section 10 pharmacy preparation | GPhC-regulated pharmacy context under the Medicines Act | Prescription-based preparation under pharmacist supervision for an identified patient | It does not permit stockpiling or wholesale-like supply |
| Specials pathway | MHRA; MSL holder | An unsolicited order meeting Regulation 167 conditions where no suitable licensed alternative exists | A special remains unlicensed and is not equivalent to a licensed medicine |
| Unlicensed commercial supply | MHRA, with ASA/CAP, GPhC, and Border Force in their page-specific roles | No general permitted commercial route is established by the page | Advertising, pharmacy, or import activity cannot substitute for medicine authorization |
Import, sale, advertising, and online supply
Import: requires a Wholesale Distribution Licence (WDA(H)) for imports from approved countries, or an MIA/MSL from non-approved countries. A Notification of Intent to Import must be submitted to MHRA for unlicensed products; 28-day assessment period.
Personal import exemption: no formal personal-use defence exists in UK law for unapproved medicines.
Online: Part 14 of HMR 2012 prohibits POM advertising to the public. The joint CAP/MHRA/GPhC enforcement notice (September 2025) specifically addresses advertising of prescription-only weight-management medicines (GLP-1 agonists).
GPhC guidance (updated February 2025): registered pharmacies offering distance-selling services must verify identity, ensure two-way communication before prescribing high-risk medicines, and not rely solely on online questionnaires.
Research-use-only products
MHRA Borderlines Head Lynda Scammell (April 2026): "We disregard claims that products are for 'research purposes' if it is clear that such claims are being used as an attempt to avoid medicines regulations." The MHRA looks at promotional material, claims, dosing guidance, and FAQ content — not just label wording. Enforcement against "research peptide" vendors is active.
Sport/anti-doping overlay
UK Anti-Doping (UKAD) enforces The World Anti-Doping Agency; its Prohibited List classifies many peptides as prohibited substances in sport. परिभाषा का स्रोत: WADA and sport regulation brief · शब्दावली rules for UK athletes.
Enforcement examples and uncertainty
| Date | Actor | Conduct | Status/action | Source |
|---|---|---|---|---|
| April 2026 | MHRA, reported in news coverage | Peptide clinics making unverified medicinal claims | Investigation announced; the cited record is news reporting rather than an MHRA case decision | Guardian report |
| Date not specified on this page | MHRA | Websites selling melanotan II and other unlicensed peptides | Enforcement action reported; scope must be checked against the underlying authority record | MHRA guidance and services |
| January 2025 | UK post-Windsor framework | UK marketing authorisations and safety features | UK MAs became UK-wide, EU FMD safety features were fully disapplied, and a separate UK pharmacovigilance regime applied | Human Medicines Regulations |
| January 2026 | GPhC fitness-to-practise process | Pharmacist imported unlicensed prescription-only medicines from China | Warning issued | Page enforcement summary; the cited source list does not identify the underlying decision URL |
Practical interpretation limits
This is general regulatory research, not legal advice. Classification can turn on composition, claims, intended use, route, supplier role, and facts not captured by a product name.
Related atlas pages: EU and EEA comparison, cross-border supply, approved-product label index, and WADA and sport.
Primary sources
Human Medicines Regulations 2012 (SI 2012/1916). https://www.legislation.gov.uk/uksi/2012/1916/contents
Medicines Act 1968, Section 10. https://www.legislation.gov.uk/ukpga/1968/67/section/10
ILAP Guidance. https://www.gov.uk/government/publications/marketing-authorisations-granted-in-2026
MHRA Import Guidance. https://www.gov.uk/guidance/import-a-human-medicine
GPhC Distance-Selling Guidance (Feb 2025). https://assets.pharmacyregulation.org/files/2025-02/gphc-guidance-registered-pharmacies-providing-pharmacy-services-distance-february-2025.pdf
GPhC Weight Management Review (Apr 2026). https://assets.pharmacyregulation.org/files/2026-04/Weight-management-medicines-and-services-a-review-of-GPhC-inspections-and-concerns-April-2026.pdf
MHRA on Peptide Clinics (Apr 2026). https://www.theguardian.com/society/2026/apr/04/medicines-watchdog-to-investigate-uk-peptide-clinics-over-health-claims